Dementia with Lewy Bodies

Jared Hinkle , Gregory Pontone, M.D.
Dementia with Lewy Bodies is a topic covered in the Johns Hopkins Psychiatry Guide.

To view the entire topic, please log in or purchase a subscription.

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

Johns Hopkins Guides

COVID-19 Update with Dr. Paul Auwaerter of Johns Hopkins : Omicron Variant, Testing, and TreatmentCOVID-19 Update with Dr. Paul Auwaerter of Johns Hopkins : Omicron Variant, Testing, and Treatment

Coronavirus COVID-19 (SARS-CoV-2)Coronavirus COVID-19 (SARS-CoV-2)

Suicide Risk in the COVID-19 PandemicSuicide Risk in the COVID-19 Pandemic

Moderna COVID-19 VaccineModerna COVID-19 Vaccine

BNT162b2 COVID-19 Vaccine (BioNTech/Pfizer)BNT162b2 COVID-19 Vaccine (BioNTech/Pfizer)

Managing Stress and Coping with COVID-19Managing Stress and Coping with COVID-19

Johnson & Johnson COVID-19 VaccineJohnson & Johnson COVID-19 Vaccine

-- The first section of this topic is shown below --

DEFINITION

  • Dementia with Lewy bodies (DLB) is a primary neurodegenerative disorder affecting cognitive function and movement.
    • Early symptoms include prominent deficits in attention, as well as visuospatial and executive dysfunction.
    • Parkinsonism, hallucinations, cognitive fluctuations, and REM sleep behavior disorder are commonly present.
  • DLB is one of the three major α-synucleinopathies, along with Parkinson disease (PD) and multiple system atrophy but is more likely to be misdiagnosed as Alzheimer disease (AD).
    • α-synuclein protein aggregation in cytoplasmic neuronal inclusions (Lewy bodies) is a pathological hallmark of both DLB and PD.
    • Classically, DLB pathology features heavy neocortical Lewy body burden with low AD pathology Aβ or tau pathology, but co-pathology is frequent and may contribute to heterogeneity of disease [1][2][3].
  • Compared with AD, DLB has a shorter mean survival time after diagnosis (~4 years vs. ~6 years) [4] and generally places more significant financial burdens on patients and their families/caretakers [5].
  • Cognitive impairment due to Lewy bodies is classified under the neurocognitive disorders (NCDs) section of the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) [6].

-- To view the remaining sections of this topic, please log in or purchase a subscription --

DEFINITION

  • Dementia with Lewy bodies (DLB) is a primary neurodegenerative disorder affecting cognitive function and movement.
    • Early symptoms include prominent deficits in attention, as well as visuospatial and executive dysfunction.
    • Parkinsonism, hallucinations, cognitive fluctuations, and REM sleep behavior disorder are commonly present.
  • DLB is one of the three major α-synucleinopathies, along with Parkinson disease (PD) and multiple system atrophy but is more likely to be misdiagnosed as Alzheimer disease (AD).
    • α-synuclein protein aggregation in cytoplasmic neuronal inclusions (Lewy bodies) is a pathological hallmark of both DLB and PD.
    • Classically, DLB pathology features heavy neocortical Lewy body burden with low AD pathology Aβ or tau pathology, but co-pathology is frequent and may contribute to heterogeneity of disease [1][2][3].
  • Compared with AD, DLB has a shorter mean survival time after diagnosis (~4 years vs. ~6 years) [4] and generally places more significant financial burdens on patients and their families/caretakers [5].
  • Cognitive impairment due to Lewy bodies is classified under the neurocognitive disorders (NCDs) section of the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) [6].

There's more to see -- the rest of this entry is available only to subscribers.

© 2000–2022 Unbound Medicine, Inc. All rights reserved